PROK (ProKidney) Other Current Receivables: $0.96 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROK ProKidney Corp PROK
28 GF Score
Price $2.01
! 3 Warning Signs
View Full Analysis

What is ProKidney Other Current Receivables?

ProKidney PROK +4.96% 28 Other Current Receivables is $0.96 Mil as of Jun. 2026. GuruFocus rates PROK with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

ProKidney's Other Current Receivables for the quarter that ended in Jun. 2026 was $0.96 Mil.

ProKidney's quarterly Other Current Receivables declined from Dec. 2025 ($1.13 Mil) to Mar. 2026 ($1.03 Mil) but then stayed the same from Mar. 2026 ($1.03 Mil) to Jun. 2026 ($0.96 Mil).

ProKidney's annual Other Current Receivables increased from Dec. 2023 ($1.38 Mil) to Dec. 2024 ($2.45 Mil) but then declined from Dec. 2024 ($2.45 Mil) to Dec. 2025 ($1.13 Mil).

ProKidney Other Current Receivables Related Terms

ProKidney Other Current Receivables Historical Data

* Premium members only.

The historical data trend for ProKidney's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProKidney Other Current Receivables Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.00 0.00 1.38 2.45 1.13

ProKidney Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 1.24 1.13 1.03 0.96
PROK
28GF Score
ProKidney Corp PROK
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProKidney Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.96 Mil mean?
ProKidney (PROK) has a Other Current Receivables of $0.96 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ProKidney and its competitors.
Is ProKidney's Other Current Receivables too high?
ProKidney's current Other Current Receivables is $0.96 Mil. Overall, ProKidney has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ProKidney's Other Current Receivables compare to EYPT and ENTA?
ProKidney's Other Current Receivables of $0.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ProKidney and its competitors. ProKidney's current Other Current Receivables is $0.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProKidney stock overvalued right now?
ProKidney (PROK) has a current Other Current Receivables of $0.96 Mil. The current Other Current Receivables is $0.96 Mil. ProKidney's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For ProKidney (PROK), the current Other Current Receivables is $0.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProKidney Business Description

Other Exchanges PROK:Mexico
Address 2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
28GF Score

Get the complete analysis for PROK

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.01
Price